Mirina Closes Series A-1 Financing to Support miRNA Drug Development | GenomeWeb

Mirina, a startup focused on developing microRNA-targeting drugs, announced this week that it has closed a Series A-1 financing.

While the amount of the funding was not disclosed, an official from the investment firm that founded Mirina said that it is sufficient to fund the company's operations for 12 to 15 months, during which time the drug developer will focus on selecting and validating molecule candidates for late-stage preclinical testing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.